Phase II Randomized Trial of Weekly and Every 3-Week Ixabepilone in Metastatic Breast Cancer (MBC) Patients.
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2016
At a glance
- Drugs Ixabepilone (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 24 May 2012 Actual end date changed from Dec 2010 to Aug 2010 as reported by ClinicalTrials.gov.
- 25 Sep 2010 Status changed from active, no longer recruiting to completed, as final results reported at ASCO-BCS.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History